HilleVax Inc (HLVX) 뉴스

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is...

Form 8-K - Current report

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is...

Form 8-K - Current report

HilleVax Announces Reduction in Force

BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical...

Form 8-K - Current report

Form 8-K - Current report

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report